Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice-daily as syrups versus scored tablets in HIV-1 infected Ugandan children.

From:
Department for International Development
Published
1 January 2010
Country:
Uganda
Document Type:
Conference Paper
Theme:
Health
Authors:
Walker, A.S., Gibb, D.M., Nahirya-Ntege, P., Kekitiinwa, A., Bwakura-Dangarembizi, M.F., Musiime, V., Kasirye, P., Bakeera-Kitaka, S., Ferrier, A., Burger, D., Kendall, L., Adkison, K., Opilo, W., Lou, Y., Ssenyonga, M., Snowden, W.

Abstract

Replacing syrups by tablets as the formulation of antiretroviral drugs in HIV-1-infected Ugandan children made no significant difference to the pharmacokinetics of zidovudine or abacavir (after allowing for the larger dose contained in the tablets), but dose-normalised lamivudine exposure was about 55% higher with tablets than with syrup.

Citation

Kasirye, P.; Kendall, L.; Musiime, V.; Adkison, K.; Kekitiinwa, A.; Ferrier, A.; Opilo, W.; Lou, Y.; Bwakura-Dangarembizi, M.F.; Nahirya-Ntege, P.; Bakeera-Kitaka, S.; Ssenyonga, M.; Snowden, W; Burger, D.; Walker, A.S.; Gibb, D.M. Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice-daily as syrups versus scored tablets in HIV-1 infected Ugandan children. Presented at Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 7-11 November 2010. (2010)

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice-daily as syrups versus scored tablets in HIV-1 infected Ugandan children.

Updates to this page

Published 1 January 2010
Contents